Goldman Sachs Group Inc. Invests $147,000 in Climb Bio, Inc. $CLYM

Goldman Sachs Group Inc. purchased a new position in shares of Climb Bio, Inc. (NASDAQ:CLYM) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 120,742 shares of the company’s stock, valued at approximately $147,000. Goldman Sachs Group Inc. owned about 0.18% of Climb Bio at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in CLYM. AQR Capital Management LLC bought a new stake in Climb Bio in the first quarter valued at approximately $27,000. XTX Topco Ltd bought a new stake in Climb Bio in the first quarter valued at approximately $34,000. Nuveen LLC bought a new stake in Climb Bio in the first quarter valued at approximately $48,000. Bank of New York Mellon Corp bought a new stake in Climb Bio in the first quarter valued at approximately $79,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Climb Bio in the first quarter valued at approximately $86,000. 69.76% of the stock is currently owned by institutional investors.

Climb Bio Trading Down 6.6%

NASDAQ CLYM opened at $1.99 on Tuesday. The firm has a market capitalization of $134.84 million, a P/E ratio of -2.84 and a beta of -0.05. The business has a fifty day simple moving average of $2.00 and a 200 day simple moving average of $1.52. Climb Bio, Inc. has a 12 month low of $1.05 and a 12 month high of $5.86.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. As a group, sell-side analysts predict that Climb Bio, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on CLYM. Oppenheimer began coverage on Climb Bio in a report on Friday, June 6th. They issued an “outperform” rating and a $10.00 target price on the stock. Baird R W upgraded Climb Bio to a “strong-buy” rating in a report on Friday, August 15th. Robert W. Baird started coverage on Climb Bio in a report on Friday, August 15th. They issued an “outperform” rating and a $9.00 target price on the stock. BTIG Research restated a “buy” rating and set a $7.00 price target on shares of Climb Bio in a report on Monday, September 22nd. Finally, Wall Street Zen cut Climb Bio from a “hold” rating to a “sell” rating in a report on Sunday. Two equities research analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to MarketBeat, Climb Bio presently has an average rating of “Buy” and a consensus price target of $9.00.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.